Table 1 Clinical features of the SLE subjects, median (IQR)

Baseline characteristics

Age (year)

12 (10–13)

12 (11–13)

11 (9–12)

0.0603

Gender (Male/Female), n (%)

7/40 (17.50)

4/30 (13.33)

3/10 (30)

0.3769

Disease duration since diagnosis (year)

1 (0.1-3)

2 (0.6-3)

0.3 (0.1–0.9)

0.0273

Clinical features of SLE subjects

SLEDAI ≤ 4 (N = 15)

2 (2–2)

2 (2–2)

0 (0–0)

< 0.0001

SLEDAI > 4 (N = 32)

14 (8-17.50)

9 (7.50–14)

20 (15-28.50)

< 0.0001

SLICC features, n (%)

Acute cutaneous lupus

16/47 (34.04)

8/34 (23.53)

8/13 (61.54)

0.0198

Chronic cutaneous lupus

4/47 (8.51)

3/34 (8.82)

1/13 (7.69)

1.000

Neurologic disorder

2/47 (2.13)

0/34 (0)

2/13 (15.38)

0.0722

Oral/nasal ulcers

4/47 (8.51)

2/34 (5.88)

2/13 (15.38)

0.5723

Joint disease

6/47 (12.77)

1/34 (2.94)

5/13 (38.46)

0.0042

Serositis

5/47 (10.64)

0/34 (0)

5/13 (38.46)

0.0008

Hemolytic anemia

11/47 (23.40)

4/34 (11.76)

7/13 (53.85)

0.005

Leukopenia

7/47 (14.89)

3/34 (8.82)

4/13 (30.77)

0.1723

Thrombocytopenia

3/47 (6.38)

1/34 (2.94)

2/13 (15.38)

0.0503

Antiphospholipid syndrome

2/47 (2.13)

2/34 (5.88)

0/13 (0)

1.000

ANA

45/47 (95.74)

33/34 (97.06)

12/13 (92.31)

0.0774

Anti-dsDNA

45/47 (95.74)

33/34 (97.06)

12/13 (92.31)

0.0003

Low complement

28/47 (59.57)

17/34 (50)

11/13 (84.62)

0.0463

Anti-Smith

7/47 (14.89)

5/34 (14.71)

2/13 (15.38)

1.000

Renal involvemen

21/47(44.68)

10/34(29.41)

11/13(84.62)

0.0009